Introduction
Venous thromboembolism (VTE), defined as deep vein thrombosis (DVT) and/or pulmonary embolism (PE), is a common disease [1] . The incidence of VTE increases with age, rising from <1 case per 1,000 person-years in persons aged <50 years to more than 6 cases per 1,000 person-years in persons aged >80 years [2] [3] [4] [5] [6] . Overall, 60 % of VTE events occur in persons aged ≥65 years [1, 2, 7] .
Several factors induced by smoking could promote the formation of a clot and the subsequent VTE. These mechanisms were often studied in researches on atherosclerosis, and smoking shares common biological consequences on the venous system. Smoking causes endothelial damage that can lead to a reduced capacity for dilatation (by a decreased activity of nitrous oxide) and increased vessel contraction (by stimulation of the release of catecholamines) [8] [9] [10] [11] . This endothelial damage can lead to prothrombotic and pro-inflammatory states with an increased production of cytokines including IL-6, IL1B and TNFα [8] [9] [10] [11] . Those cytokines play major regulatory roles in the hepatic synthesis of acute phase proteins, including fibrinogen. As IL-6 appears to be the principal procoagulant cytokine in humans, it could be an important link to VTE [11, 12] .
Moreover, there is a clear dose-effect relationship between number of cigarettes smoked per day and raised plasma fibrinogen concentration and conversely a reduction of it with smoking cessation [13] .
The association between smoking and VTE remains controversial. While a metaanalysis reported no statistically significant relationship between smoking and first VTE (odds ratio [OR] 1.18, 95% confidence interval [CI] 0.95-1.46) [14] , a recent meta-analysis demonstrated that cigarette smoking was associated with a slightly increased risk for first VTE (pooled relative risk 1.23, 95% CI 1.14-1.33) in current smokers compared with never smokers [15] .
Smoking interacts directly with the metabolism of vitamin K antagonists by increasing the required dosage to achieve and maintain a therapeutic international normalized ratio [16] , potentially increasing the risk of VTE recurrence.
Pathophysiologically, smoking may increase the clearance of warfarin and in this way reduce its anticoagulant effect. Therefore, smoking cessation or a decrease in smoking may lead to overanticoagulation and an increased risk of bleeding.
Evidence suggests that elderly patients who have experienced an acute VTE may have a higher risk of VTE recurrence, bleeding, and death than younger patients [2, 7] .
Given that the elderly are a rapidly growing population segment in Western societies and almost half of the elderly population is or has been exposed to smoking [17] , it is of interest to examine the possible association between smoking and VTE recurrence and bleeding in this population. In a prospective multicenter cohort study, we aimed to assess the association between smoking status and the risk of recurrent VTE and bleeding in elderly patients with acute VTE.
Methods

Cohort sample
The study was conducted between September 2, 2009 and December 6 2013 as part of Swiss Cohort of Elderly Patients with Venous Thromboembolism (SWITCO65+), a prospective, multicenter cohort study that assessed long-term medical outcomes in elderly patients with acute VTE from all five university and four high-volume nonuniversity hospitals in Switzerland. Consecutive patients aged ≥65 years with acute, objectively confirmed symptomatic VTE were prospectively identified in the inpatient and outpatient services of all participating study sites. Exclusion criteria were catheter-related thrombosis, insufficient German or French-speaking ability, no follow-up possible (i.e., terminal illness), an inability to provide informed consent (i.e., severe dementia), or previous enrollment in the cohort. The detailed methodology of the SWITCO65+ cohort has been described elsewhere [2] . The study has been approved by the Institutional Review Board at each participating center. For the present study, we excluded patients with missing information about their smoking status.
Baseline data collection
For all enrolled patients, trained study nurses prospectively collected information about baseline demographics (age, gender, insurance status, living status, and educational level), comorbid conditions (active cancer, hepatic, cardiac, lung, renal, and cerebrovascular disease, and history of major bleeding), traditional cardiovascular risk factors (arterial hypertension, diabetes mellitus, hypercholesterolemia, body mass index, physical activity level), risk factors for VTE (active cancer, recent immobilization, major surgery, estrogen therapy), type and localization of the index VTE, VTE-related treatments (oral and parenteral anticoagulants), and concomitant antiplatelet/nonsteroidal anti-inflammatory drug therapy using standardized data collection forms.
Smoking habits, including self-reported smoking status, the average number of cigarettes smoked per day and years of smoking were assessed. We defined three possible smoking statuses: current smokers (i.e. patients reporting smoking ≥1 cigarette per day at the time of the interview), former smokers (defined as smokers who had quit for >6 months) and never smokers. Current and former smokers were classified into three subgroups according to the number of pack-years smoked (defined as the number of packs of cigarettes smoked per day multiplied by the duration of smoking in years ): ≤20, 21-40, and >40 pack-years.
Study outcomes
The primary outcome was the time to the recurrence of symptomatic, objectively confirmed VTE during follow-up, defined as new or recurrent PE or DVT based on previously published criteria [18, 19] . We defined recurrent symptomatic VTE as acute chest pain, new or worsening dyspnea or cough, acute hemoptysis, or syncope coupled with an objective diagnosis of pulmonary embolism based on spiral computed tomography, pulmonary angiography, or autopsy, or a new unilateral leg pain or swelling coupled with an objective diagnosis of deep vein thrombosis based on ultrasonography or contrast venography.
The secondary outcome was the time to a first bleeding event. We defined major bleeding as fatal bleeding, symptomatic bleeding in a critical organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), bleeding with a reduction of hemoglobin ≥20 g/l, or bleeding leading to the transfusion of 2 units of packed red blood cells or more [2, 20] . Non-major bleeding was defined as bleeding leading to a medical consultation or a visit to an emergency center, without fulfilling the criteria for major bleeding [2] .
Follow-up included one telephone interview and two surveillance, face-to-face evaluations during the first year of study participation and then semi-annual contacts, alternating between face-to-face evaluations (clinic visits or home visits in house-bound patients) and telephone calls as well as periodic reviews of the patient's hospital chart.
During each visit/contact, study nurses interviewed patients to obtain information about the date and type of clinical events (recurrent VTE, bleeding, and death). If a clinical event had occurred, this information was complemented by reviewing medical charts and interviewing patients' primary care physicians and family members. We assessed outcomes using patient or proxy interviews, interview of the patient's primary care physician, and/or hospital chart review. A committee of three blinded clinical experts adjudicated all outcomes and classified the cause of all deaths as definitely due to PE, possibly due to PE, due to major bleeding, or due to another cause. Final classification was made on the basis of the full consensus of this committee.
Statistical analysis
We compared baseline and outcome characteristics of never, current, and former smokers using chi-squared test for categorical variables and non-parametric KruskalWallis test for continuous variables. Smoking characteristics of current and former smokers were compared using chi-squared and Wilcoxon rank-sum test as appropriate.
We calculated the incidence rate of a first VTE recurrence in each group and compared incidences among groups using the incidence rate ratio. We estimated the cumulative incidence of a first VTE recurrence by the Kaplan-Meier method and compared survivor functions across groups of patients with different smoking status and the quantity of Associations between smoking status and the time to the first VTE recurrence were assessed by competing risk regression accounting for death as a competing event, according to the method of Fine and Gray (1999) [21] . The method yields sub-hazard ratios (SHR) with corresponding 95% confidence intervals (CIs). Adjustments were done for age and gender and for variables associated with VTE recurrence, including prior VTE, active cancer, overt PE, and provoked VTE (defined as the presence of immobilization, major surgery, or current estrogen therapy during the last three months). For bleeding, adjustments were done for age and gender and for variables known to be associated with a higher bleeding risk, including chronic renal disease or or a creatinine clearance <30ml/min., history of major bleeding, anemia, and concomitant antiplatelet treatment [22] [23] [24] [25] . We adjusted all analyses for periods of anticoagulation treatment as a timevarying covariate. All analyses were done using Stata 13 (Stata Corporation, College Station, Texas).
Results
Of the 1003 patients enrolled in the cohort, 15 were excluded who did not allow use of their data (n=8), withdrew early (n=4), or missed information about smoking status (n=3). Therefore, the final study sample comprised 988 patients of whom 509 (52%) had never smoked, 403 (41%) were former smokers and 76 (8%) current smokers. The median follow-up duration was 29.6 months (IQR 18.8-36.2).
Patient baseline characteristics are described in table 1. Former and current smokers reported a median of 16 and 30 pack-years, respectively. Never smokers were more likely to be women and older than current and former smokers. Not surprisingly, current and former smokers were more likely to have lung disease and coronary heart disease and to receive concomitant antiplatelet therapy than never smokers. Finally, never smokers were more likely to receive vitamin K antagonists.
Overall, 204 patients (20%) died during follow-up and 120 (12%) had recurrent VTE (table 2). VTE recurrence did not vary by smoking status. Furthermore, 131 patients (13%) had major and 199 (20%) non-major bleeding events during the follow-up. Again, bleeding did not differ by smoking status. Table 2 shows the incidence rate and incidence rate ratio (IRR) of VTE recurrence and major and non-major bleeding events for the three categories of smokers. Generally, compared with never smokers, current smokers tended to have a somewhat higher incidence rate of VTE recurrence (IRR 1.1 95% CI 0.4-2.8) and non-major bleeding events (IRR 1.2 95% CI 0.7-2.0) but a lower incidence of major bleeding events (IRR 0.7 95% CI 0.2-1.5).
After adjustment, current smokers did not have a statistically significantly increased risk of VTE recurrence compared with never smokers (adjusted SHR 1.05 95% CI 0.49-2.28). Similarly, there was no statistically significant association between active smoking and major (adjusted SHR 0.59 95% CI 0.25-1.39) and non-major bleeding events (adjusted SHR 1.21 95% CI 0.73-2.02). We did not observe a statistically significant association between former smoking status and VTE recurrence or bleeding events.
Moreover, we found no dose-response relationship between the number of pack-years and VTE recurrence in current and former smokers (data not shown). In patients who received treatment with vitamin K antagonists, the percentage of time spent in the therapeutic range did not vary by smoking status (data not shown).
Discussion
In this prospective cohort of elderly patients with VTE, the incidence of recurrent VTE and bleeding did not vary by smoking status. We found no dose-response relationship between the number of pack-years smoked and VTE recurrence. After adjustment, smoking status was neither associated with recurrent VTE nor with bleeding.
In the present study, the prevalence of active smoking (8%) was similar to that observed in the general Swiss population aged 65 years or older [26] but former smokers were over represented in this cohort (41% vs 33.3% for 65-74 years old and 26.7% for ≥75 years old in the general Swiss population).
While the relationship between smoking and the first VTE has been well studied, very few studies have examined the relationship between smoking status and recurrent VTE. A cross-sectional study on the impact of cardiovascular risk factor on the risk of recurrent VTE reported no statistically significant association between cigarette smoking and recurrence of VTE (hazard ratio [HR] 1.20, 95%CI 0.88-1.52) [27] . In this study of younger patients (mean age 43.5 years), the authors did not differentiate current smokers from former smokers and compared ever smokers (current and former smokers) to never smokers. The reason why smoking seems to be associated with a first VTE but not with recurrent VTE remains unclear. However, after a first VTE event, smokers might reduce their cigarette consumption or make quit attempts, thus decreasing the risk of recurrent VTE. This might partly explain why smoking was not associated with an increased risk of VTE recurrence in the present study.
Regarding the possible dose-response relationship between smoking and VTE recurrence, we found no association between number of pack-years and VTE recurrence. A large population-based case-control study showed a clear dose-dependent, reversible association of smoking and the risk of a first VTE [28] . The limited number of smokers in our study (n=76) might explain the absence of significant dose-response relationship.
In this cohort, smoking was not associated with an increased risk of major and clinically relevant non-major bleeding. Evidence suggests that smokers may need higher doses of warfarin per week than nonsmokers [16] . Smoking not only increases the dosage of required oral anticoagulant, but the variation of smoking amount or frequency may have an influence on the stability of anticoagulation making it difficult to maintain the anticoagulation in the therapeutic range. However, to our knowledge, there are no studies exploring the effect of smoking on the quality of oral anticoagulation. In our study, we found no difference in the percentage of time in the therapeutic range between smokers, former smokers, and never smokers. This may be due again to the limited sample of smokers. This study contains no information on quitting smoking, variation of consumption of cigarettes during the week or increased or decreased mean consumption of cigarettes.
The main strength of the study is that it prospectively followed patients over 3 years. It is the first prospective study examining the association between smoking status and outcomes in patients with VTE.
Our study has potential limitations. First, the study sample may not reflect the full prognostic spectrum of patients with VTE because analyzed patients were younger and more likely to be men than excluded patients. Thus we cannot rule out the possibility that the association between smoking status and bleeding and VTE recurrence would have been different in more severely ill patients. Second, an important limitation of this study is the small number of current smokers and the consequent lack of statistical power of our analysis. Moreover, the smoking status and number of cigarettes smoked a day were self-reported by patients and might be underestimated. Finally, smoking status was only assessed at baseline and was not updated over follow-up (no information on initiation, cessation or relapse of smoking). However, we can assume that initiation of smoking in a population age > 65 years old is very unusual. Finally, our results are valid only for a Caucasian European population, given the relatively high socio-economical status of the population included and are not generalizable to other populations.
In conclusion, we found no differences in anticoagulation quality in smokers, former smokers, and never smokers in this prospective cohort of elderly patients with VTE. Moreover, smoking status was not significantly associated with VTE recurrence or bleeding. This study investigated for the first time the impact of smoking in this population. 
